FENFLURAMINE ASSESSMENT IN RARE EPILEPSY (FAiRE)

**ZX008-Study 2/1504** The FAiRE program is exploring whether an investigational drug (ZX008 Fenfluramine) can improve seizure control in children and young adults with Dravet syndrome.

**GOAL OF ZX008-STUDY 2/1504 TRIALS:**
Test if ZX008 is a safe and effective treatment for children and adolescents with Dravet syndrome, when added on to their other seizure medications.

**OUTCOMES TO BE LOOKED AT:**
- Change in number of convulsive (for example, tonic clonic) seizures or non-convulsive (for example absence or focal) seizures compared to before the study medication was started
- Number of days without convulsive seizures
- Use of Rescue Medication
- Number of hospitalizations to treat seizures

**ELIGIBILITY CRITERIA INCLUDE¹,²:**
- Age 2-18 years (inclusive)
- Documented medical history that supports a clinical diagnosis of Dravet syndrome
- First seizure happened in the person’s first year of life
- Uncontrolled seizures despite current medication

¹(Study 2 does not allow patients taking stiripentol to participate, ²Study 1504 requires patients to be taking stiripentol as part of their current treatment regimen)

**PARTICIPATION ENTAILS:**
- Continuation of person’s normal background anti-seizure medication(s)
- Treatment with either placebo or study medication
- Use of a seizure diary to record seizure activity and medication details
- Regular health checks: include electrocardiograms (ECG) (test of heart rhythms), echocardiograms (an ultrasound of the heart), physical examination (including blood pressure and heart rate), and nervous system assessments.

https://www.faireds.com/en-us/recruitment/can-i-take-part

For more information on Dravet syndrome and FAiRE, or to enroll, visit